Power Corporation of Canada
POW
Choice Properties Real Estate Investment Trust
CHP.UN
Bank of Nova Scotia
BNS
Emera Inc
EMA
The Toronto-Dominion Bank
TD
NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.